California Public Employees Retirement System bought a new stake in shares of Enovis Co. (NYSE:ENOV – Get Rating) in the 2nd quarter, Holdings Channel reports. The fund bought 82,574 shares of the company’s stock, valued at approximately $4,542,000.
Several other institutional investors have also modified their holdings of the business. Texas Permanent School Fund purchased a new stake in Enovis during the 2nd quarter worth approximately $1,869,000. AMG National Trust Bank acquired a new stake in Enovis in the second quarter valued at $342,000. River Road Asset Management LLC bought a new position in Enovis during the 2nd quarter valued at $15,827,000. Northwestern Mutual Investment Management Company LLC acquired a new position in Enovis during the 2nd quarter worth $433,000. Finally, Intrinsic Value Partners LLC bought a new stake in shares of Enovis in the 2nd quarter worth about $336,000. Institutional investors and hedge funds own 89.40% of the company’s stock.
Analyst Upgrades and Downgrades
Several analysts have issued reports on ENOV shares. Jefferies Financial Group initiated coverage on Enovis in a research note on Wednesday, October 12th. They set a “buy” rating and a $60.00 price objective on the stock. Wells Fargo & Company dropped their price target on Enovis from $60.00 to $53.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 26th. TheStreet downgraded shares of Enovis from a “c” rating to a “d” rating in a report on Wednesday, November 2nd. Robert W. Baird dropped their target price on shares of Enovis from $73.00 to $68.00 and set an “outperform” rating on the stock in a report on Thursday, November 3rd. Finally, Canaccord Genuity Group began coverage on shares of Enovis in a research report on Monday, September 12th. They issued a “buy” rating and a $67.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $63.50.
Enovis Stock Performance
Insider Activity at Enovis
In other Enovis news, EVP Daniel A. Pryor sold 67,421 shares of the firm’s stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $54.58, for a total value of $3,679,838.18. Following the sale, the executive vice president now owns 75,731 shares in the company, valued at $4,133,397.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 8.30% of the stock is currently owned by insiders.
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.
- Get a free copy of the StockNews.com research report on Enovis (ENOV)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.